

What: Operations Committee Meeting When: April 25, 2023; 12:30-1:30 p.m. PT Where: Zoom Meeting

To register for the meeting, please review the <u>Public Comment Protocol</u> then email <u>wvameetings@wavaccine.org</u> at least two business days in advance of the meeting.

WVA Agendas are subject to revision up to and including the time of the meeting.

Notice: The meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes are approved.

Agenda for Operations Committee Meeting

Approx. Time	Page		Topic/[Anticipated Action]	Presented by:
12:30-12:35 p.m.			 Introductions & Agenda Review Notice of Recording Survey of Other Topics 	J. Zell
12:35-12:40 p.m.	Pg. 3-5	*	 Action Items Operations Committee Minutes (October 27, 2022) 	J. Zell
12:50-1:20 p.m.	Pg. 6-16 Pg. 17-25	*	 Assessment Grid 2023-24 a. Process and Communications Plan b. Vote - Assessment Grid 2023-24 	J. Zell / P. Miller
12:40-12:50 p.m.	Pg. 26-27	*	 4. Operations Updates a. Provider Compliance and Performance Improvement Plan Discussion b. Payer Compliance c. New Vaccine Preview 	J. Zell / P. Miller J. Jorgenson
1:20-1:30 p.m.			4. Other Matters from Committee Members	Any
1:30 p.m.			5. Closing	J. Zell

*Indicates Agenda Item Attached



1 Washington Vaccine Association 2 **Operations Committee Meeting** 3 October 27, 2022; 12:30-1:30 p.m. PT 4 5 I. Attendance. Participating in all or part of the meeting by telephone were the following individuals: 6 7 Members 17 WVA Walter Kuiee, Regence 8 18 Julia G. Zell, Esq., Executive Director, Chair 9 Jennifer Simonsen, Kaiser 19 10 Tracey Cardillo, Cigna 20 Helms & Company, Inc. 21 Patrick Miller, MPH, Administrative Director 11 Sue Bride, Premera 12 Cathy Falanga, Aetna 22 Ashley Ithal, MPH, Project Support Leader 13 Nicole Carroll, UnitedHealthcare 23 24 14 Janel Jorgenson, DOH Public Members 15 25 Breelynn Young, GSK 16 26 27 28 I. Summary of Actions Taken and/or Recommended 29 30 Actions Taken (votes adopted) 31 To approve April 28, 2022, meeting minutes. i. 32 ii. To approve the addition of any pediatric COVID vaccine added to the Washington Childhood Vaccination 33 Program to the WVA Assessment Grid at a blended price, TBD. 34 To approve the addition of Priorix and Vaxneuvance to the WVA Assessment Grid when it is added to the iii. 35 Washington Childhood Vaccination Program at 2% above the CDC contract price. 36 37 П. Welcome and Introductions 38 39 At 12:34 p.m., Ms. Zell called the meeting to order and provided a notice of recording. Mr. Miller introduced the 40 attending staff members from Helms. 41 42 III. **Calendar Consent Items** 43 44 Ms. Zell asked for a motion to approve the April 28, 2022, meeting minutes. There being no other questions or 45 comments, the following item was put to a vote: 46 47 Upon motion duly made and seconded, it was unanimously 48 49 VOTED: To approve April 28, 2022, meeting minutes. 50 51 52 IV. **Operations Updates** 53 54 Provider Compliance 55 Ms. Zell reminded the group that the WVA has taken on new provider outreach and compliance efforts this year as 56 historically the WVA has not had a direct relationship with providersI It has become more apparent that outreach and relationship building with the providers can address non-compliance issues in a proactive manner. New provider 57 education materials have been created, including a checklist that is designed to prevent common and systematic errors. 58 59 Ms. Zell let the group know that a provider liaison will be hired by the WVA in the spring of 2023. The goal of this 60 position is to assist the WVA in its efforts to create partnerships and prevent upstream errors. 61 62 Payer Compliance

63 Ms. Zell updated the group that a policy regarding collection of past due DBAs will be reviewed at the November

64 2022 Board meeting. There are both payer and provider generated issues with regards to Vaccine Grid adherence,

denials, and patient responsibility that result in denials or delayed payments. The drafted policy states that if the issue

- at hand stems from a provider generated issue, then the WVA will generally only look back for a one-year period. If
- 67 the issue at hand stems from a payer generated issue, then the WVA will generally limit the look back period for five
- 68 years.
- 69
- 70 <u>Vaccine Grid 2023/24</u>

Ms. Zell reminded the group that the Grid amounts have remained steady for the past three years, with the WVA absorbing CDC vaccine price inflation. It is expected that the 2023/24 grid will increase overall due to increased funding requests from the Department of Health driven by both utilization and CDC pricing.

- 74
- 75 Fund Source Split

Ms. Zell reminded the group that the fund source split describes the proportion of vaccine costs that are allocated by
 the Department of Health (DOH) to the WVA versus the Childhood Vaccine Program (CVP). The WVA's portion of

the allocation will be increasing in January 2023. Mr. Miller added that the fund source split is not recalculated on a

regular basis and the WVA needs to incorporate the new split into the WVA's financial model for budgeting purposes.

80 This new split is also part of the expected increase in the 2023/24 Vaccine Grid.
81

82 V. COVID Planning

Ms. Zell provided an overview of WVA planning for assumed discontinuation of Federal funding for COVID vaccines in the second quarter of 2023. The date has not been formally communicated yet but stems from discussions that the DOH has had with the CDC in recent months. The WVA team will use a communications plan created for the offcycle Vaccine Grid additions of Priorix and Vaxneuvance to guide the COVID vaccine grid additions. This model includes a timeline for vaccine rollout, votes to approve the off-cycle Vaccine Grid changes by the WVA Operations Committee and Board of Directors, and a DOH/WVA co-developed communication plan to payers and providers.

90

83

Ms. Zell stated that the current plan is to develop a single, blended amount for all COVID vaccines, at least until the next Vaccine Grid update effective July 1, 2023. At the moment, the CDC has not added the COVID vaccines to their price list, so we are currently unsure of what the financial impact will be. Mr. Miller stated that vaccine hesitance is also impacting uptake in some of the children age groups which also needs to be considered in the financial models the DOH will create to drive their funding requests of the WVA. There was further discussion from members of the Committee regarding the potential impacts of the COVID vaccine additions, including impacts to the Vaccine Grid, the 60-day payer notification requirement, education of payers and providers, and compliance.

98

102

99 Ms. Zell asked for a motion to approve the addition of any pediatric COVID vaccine added to the Washington 100 Childhood Vaccination Program to the WVA Assessment Grid at a blended price, TBD. There being no other 101 questions or comments, the following item was put to a vote:

- 103 Upon motion duly made and seconded, it was unanimously 104 105 **VOTED:** To approve the addition of any pediatric COVID vaccine added to the Washington Childhood Vaccination Program to the WVA Assessment Grid at a 106 107 blended price, TBD. 108 109 Ms. Zell stated that in addition to the expected COVID vaccines, that there are two, new vaccines expected to be added to the CDC's price list later this year: Priorix and Vaxneuvance. Currently, it is unclear when these two vaccines will 110 be added by the CDC, when they will be available within the DOH's order set to providers, and when DBA billing 111 112 will commence. There is still the same 60-day payer notification requirement as previously mentioned during the COVID discussion. Ms. Zell stated that there is an expectation that several additional vaccines will be coming to 113 market in the next few years, so developing a process to address these off-cycle vaccine additions is imperative. 114
- 115

116 Ms. Zell asked for a motion to approve the addition of Priorix and Vaxneuvance to the WVA Assessment Grid when they are added to the Washington Childhood Vaccination Program at 2% above the CDC contract price. There being 117 118 no other questions or comments, the following item was put to a vote: 119 120 Upon motion duly made and seconded, it was unanimously 121 122 **VOTED:** To approve the addition of Priorix and Vaxneuvance to the WVA Assessment 123 Grid when they are added to the Washington Childhood Vaccination 124 Program at 2% above the CDC contract price. 125 126 VI. Closing 127

128 Ms. Zell thanked everyone for their input and guidance today, and the meeting was adjourned at 1:27 pm PT.

Ensuring Funds for Childhood Vaccines

2023-24 Vaccine Assessment Grid

Presented to the Washington Vaccine Association Operations Committee Meeting April 25, 2023





Meeting Packet Page 5


Confidential and Proprietary © 2023

Presentation Overview

- 1. Process Timeline
- 2. Integrated Approach
- 3. Model
- 4. Grid Communications and Compliance
- 5. 2023-24 Grid (Attachment)




1. 2023-24 Budget & Vaccine Grid Development Process





2. Integrated Approach


- 1. There is a nested relationship between the administrative budget, the cash flow model, and the vaccine assessment grid
- 2. Goals of the 2023-24 vaccine grid process include:
 - 1. Providing grid stability to minimize year-to-year fluctuation
 - 2. Maintain cash and reserves to a Board-approved level
 - 3. Ensure reserves for COVID and other new vaccines






3.i. Model: Weighted CDC Contract Price Increases (specific to WVA's utilization)

Weighted CDC Contract Price Increases





3.ii. Model: Historical and Model Projections End of FY Cash Balance – FY2017-25





3.iii. Model: FY2024 Notable Projection Assumptions

- Fund Source Split Adjusted CY2023
 - 47% WVA; 50% VFC; 3% CHIP
- Changing Presentations
 - Menveo (MCV40)
 - Rotarix (RV1)
- New Vaccines
 - Priorix (MMR)
 - VaxneuvanceTM (PCV15)
 - Prevnar 20[®] (PCV20)
- New Vaccines in Pipeline
 - RSV (Date Unknown)
- Pandemic Impact on Vaccine Utilization
 - Provider Enrollment Has Outpaced Disenrollment; Enrollment Down Nearly 4% Since July 2021

- Provider Order Levels are Below Pre-Pandemic Levels; Have Recently Increased and Expected To Increase 2% in FY2024 Over FY2023
- COVID Vaccines
 - Expect Fall / Late Fall 2023 Commercialization
 - Vaccine Presentation Options Uncertain; Expected to Change in Coming Years
 - VFC Pricing <u>Estimated</u> at \$80-100/dose
 - WVA Portion <u>Estimated</u> to be \$1.7M in FY24 and \$2.1M in FY25
 - Prebuy Process is Possible
 - New VFC Providers Anticipated
 - Retail Pharmacy Role Likely



3.iv. Model: Assumptions Summary

Adjustment Variables		Assumpti	ons	
	FY2023	FY2024	FY2025	FY2026
Assessment Grid as Percent of Prior Year	100%	110%	110%	110%
TRICARE Surcharge (3-Year Lock)	2.5%	2.5%	2.5%	2.5%
DOH Indirect Charge	1.4%	1.4%	1.4%	1.4%
DOH Cost Recovery Fee (2.8% Cap)	1.4%	1.4%	1.4%	1.4%
Vaccine Wastage	2.7%	2.5%	2.4%	2.4%
Denials	13.0%	7.0%	6.0%	5.0%
Denial Recoveries	4.0%	1.0%	1.0%	1.0%
Administrative Budget	\$2.07M	\$2.19M	\$2.26M	\$2.33M
Cash "Burn Down" Amount	(\$11.3M)	\$10.6M	\$3.3M	(\$2.3M)
Year End Balance	(\$43.6M)	\$33.0M	\$29.7M	\$32.0M
CDC Vaccine Purchase Price Increase	3.6%	4.6%	3.9%	3.5%


NASHINGTON

SSOCIATION



8

3.v. Model: Weighted Average Grid Amount Vs. Weighted Average Private Sector Price – FY2017-24





4. Grid Communications and Compliance

WASHINGTON VACCINE ASSOCIATION Ensuring Funds for Childhood Vaccines

Initiator / Audience	Мау	June	July	August-September
Provider Notification	Email	Email Reminder Physical Mailing		
Payer Notification	Email Physical Mailing	Email Reminder		
Other Stakeholder Notification	Email Physical Mailing	OneHealthPort Updates Website		
Prevnar 20 Updates				Tentative Timeframe
Grid Compliance			Payer Notification	Payer Notification



Initiator / Audience	May	June	July	August-September
Provider Notification	Email	Email Reminder	Email Reminder	



5. 2022-23 Vaccine Grid

WASHINGTON VACCINE

2023-24 Vaccine Assessment Grid

Washington Vaccine Association Assessment Grid FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2023.

For Dosage-Based Assessment (DBA) Billing Used for Commercially Insured Patients Under the Age of 19.

Please note that this **WVA Assessment Grid, effective July 1, 2023, replaces the grid last updated on July 1, 2022.** The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP). The PURPLE COLUMN is the assessment amount per dose as of July 1, 2023.

:PT ode	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount <u>per</u> <u>dose</u> from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount <u>per</u> <u>dose</u> from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
epatit							
		Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for	Havrix®	\$20.72	\$36.92	\$22.79	10.0%
P P	00006-4095-02 10 pack – 1 dose syringe)	intramuscular use	Vaqta ®	\$20.72	\$36.66	\$22.79	10.0%
epatit	is B						
(00006-4981-00 10 pack – 1 dose vial) 00006-4093-02	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for	Recombivax HB®	\$40.54	\$26.35	¢13.70	40.00/
(58160-0820-52	intramuscular use	Engerix B®	\$12.54	\$27.36	\$13.79	10.0%
	10 pack – 1 dose syringe)						
tavir		•					
0680	00006-4047-41 10 pack – 1 dose tube) ADDED: 00006-4047-20 25 pack – 1 oral dose)	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$72.04	\$93.19	\$79.24	10.0%
6	58160-0854-52 10 pack – 1 dose vial)	Retaining ungring human attenuated (DV1) 2 does eshedule ling for avalues	Potorix®	¢07.00	\$134.72	¢107.67	10.0%
5	58160-0740-21 10 pack – 1 oral dose)	rotavnus vaccine, numan, attenuateu (NV 1), 2 dose scheudie, IIVe, IOF ofal use		<i>\$31.</i> 00	\$130.82	\$107.07	10.070
1681 (1 ع	58160-0740-21	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use This document is available in PDF and Excel versions at: https://		\$97.88 sment-grid/	• • • • • • • • • • • • • • • • • • • •		\$107.67 APPROVED A EFFECTIVE

<u>New</u>: Sorted by Vaccine Category.

New: Excel Version Adds Tabs With Sortable Columns.

Includes Price for Prevnar 20. Expect Fall 2023 Availability.





2023-24 Vaccine Assessment Grid

Washington Vaccine Association Assessment Grid FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2023.

For Dosage-Based Assessment (DBA) Billing Used for Commercially Insured Patients Under the Age of 19.

Please note that this **WVA Assessment Grid, effective July 1, 2023, replaces the grid last updated on July 1, 2022.** The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP). The PURPLE COLUMN is the assessment amount per dose as of July 1, 2023.

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount <u>per</u> <u>dose</u> from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
Hepati							
	58160-0825-52 (10 pack – 1 dose syringe)	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for	Havrix®	\$20.72	\$36.92	\$22.79	10.0%
90033	00006-4095-02 (10 pack – 1 dose syringe)	intramuscular use	Vaqta®	\$20.72	\$36.66	\$ 22.1 5	10.0 %
Hepati	tis B			•			
90744	00006-4981-00 (10 pack – 1 dose vial) 00006-4093-02 (10 pack – 1 dose syringe)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	Recombivax HB®	\$12.54	\$26.35	\$13.79	10.0%
	58160-0820-52 (10 pack – 1 dose syringe)		Engerix B®		\$27.36	27.36	
Rotavi	rus	V	•				
90680	00006-4047-41 (10 pack – 1 dose tube) ADDED: 00006-4047-20	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$72.04	\$93.19	\$79.24	10.0%
	(25 pack – 1 oral dose)						
	58160-0854-52 (10 pack – 1 dose vial)			407.00	\$134.72	\$407.CT	10.00/
90681	58160-0740-21 (10 pack – 1 oral dose)	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	Rotarix®	\$97.88	\$130.82	\$107.67	10.0%

APPROVED April 25, 2023 Meeting Pathete Cast De July 1, 2023

2023-24 Vaccine Assessment Grid

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount <u>per</u> <u>dose</u> from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
DTaP		1					
	58160-0812-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated	Kinrix® Quadracel™		\$59.39		
	49281-0562-10	poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6		\$41.93		\$46.12	10.0%
	(10 pack – 1 dose vial)	years of age, for intramuscular use			\$61.13		
	49281-0564-15 (10 pack – 1 dose syringe)		•				
	63361-0243-15						
90697	(10 pack – 1 dose syringe)	Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated	Vaxelis™	\$83.38	\$146.59	\$91.72	10.0%
90097	63361-0243-10	poliovirus, Haemophilus b conjugate (meningococcal protein conjugate), and Hepatitis B (recombinant) vaccine		\$03.30	ψ1-0.55	\$91.72	
	(10 pack – 1 dose vial)						
I GUEGS	49281-0511-05 (5 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel ®	\$61.94	\$111.30	\$68.13	10.0%
	49281-0286-10		Daptacel ®		\$35.75		
90700	(10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when		\$18.63	φυσ.τυ	\$20.49	10.0%
	58160-0810-52	administered to individuals younger than seven years, for intramuscular use	Infanrix®	\$10.00	\$28.02	\$20.45	10.070
	(10 pack – 1 dose syringe) 49281-0225-10	Diphtheria and tetanus toxoids adsorbed (DT) when administered to					
90702	(10 pack – 1 dose vial)	individuals younger than 7 years, for intramuscular use	DT (pediatric)	\$59.59	N/A	\$65.55	10.0%
	58160-0811-52	Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and		t co oc	¢02.62	¢ (7 0 7	10.00/
90723	(10 pack – 1 dose syringe)	inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use	Pediarix®	\$60.96	\$92.63	\$67.07	10.0%
Tdap							
	49281-0215-15 (10 pack – 1 dose syringe) 49281-0215-10	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	Tenivac ®		\$39.74		
90714	(10 pack – 1 dose vial)			\$16.42		\$18.06	10.0%
	13533-0131-01 (10 pack – 1 dose vial)	Tetanus and diphtheria toxoids (Td) adsorbed when administered to individuals 7 years or older, for intramuscular use	TDVAX™		\$27.99		

APPROVED April 25, 2023 Meeting Patheters / July 1, 2023

2023-24 Vaccine Assessment Grid

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount <u>per</u> <u>dose</u> from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023	
	58160-0842-11 (10 pack – 1 dose vial) 58160-0842-52 (10 pack – 1 dose syringe)	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when	Boostrix®	Boostrix®		\$46.08		
90715	49281-0400-10 (10 pack – 1 dose vial) 49281-0400-20	administered to individuals 7 years or older, for intramuscular use	Adacel®	\$32.73	\$52.41	- \$36.00 -	10.0%	
Heamo	(5 pack – 1 dose syringe) Sphilus influenzae				\$52.41			
	00006-4897-00 (10 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	PedvaxHIB®	\$13.54	\$28.87	\$14.89	10.0%	
00649	49281-0545-03 (5 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose	ActHIB®	\$9.46	\$18.94	\$10.41	10.0%	
90648	58160-0818-11 (10 pack – 1 dose vial)	schedule, for intramuscular use	Hiberix®	\$9.40	\$12.45	\$10.41	10.0%	
Pneum	noccoal		•		·			
90670	00005-1971-02 (10 pack – 1 dose syringe)	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	Prevnar 13™	\$144.84	\$226.43	\$159.32		
		to be on the market by fall 2023. The CPT and NDC codes will be updated	then. The WVA Grid	Amount is the sar	ne as Prevnar	13.	10.0%	
CPT TBD	NDC TBD (Presentation TBD)	Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use	Prevnar 20 [™]	N/A	TBD	\$159.32		
90671	00006-4329-03 (10 pack – 1 dose syringe)	Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF	TM Vaxneuvance	\$165.52	\$216.09	\$182.07	10.0%	
90732	00006-4837-03 (10 pack – 1 dose syringe)	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use	Pneumovax®23	\$59.78	\$117.08	\$65.76	10.0%	
Inactiv	Inactivated Poliovirus							
90713	49281-0860-10 (10 dose vial)	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	IPOL®	\$13.90	\$40.64	\$15.29	10.0%	

APPROVED April 25, 2023 Meeting P관야 문 위사율 July 1, 2023

2023-24 Vaccine Assessment Grid

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount <u>per</u> <u>dose</u> from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	Percent Change 07/01/2022 to 07/01/2023
MMR							
90707	00006-4681-00 (10 pack – 1 dose vial)	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	M-M-R®II	\$21.77	\$89.87	\$23.95	10.0%
	58160-0824-15 (10 pack – 1 dose vial)		Priorix	\$24.14	\$09.07	\$23.95	-0.8%
90710	00006-4171-00 (10 pack – 1 dose vial)	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	ProQuad®	\$138.67	\$262.37	\$152.54	10.0%
Varice	la						
90716	00006-4827-00 (10 pack – 1 dose vial)	Varicella virus vaccine (VAR), live, for subcutaneous use	Varivax®	\$110.28	\$159.99	\$121.31	10.0%
HPV							
		Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	Gardasil®9	\$189.08	\$268.77	\$207.99	10.0%
Menin	gococcal B						
		Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	Bexsero ®	\$120.84	\$211.32	\$132.92	10.0%
	00005-0100-10 (10 pack – 1 dose syringe)	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use	Trumenba®	\$115.17	\$179.70	\$126.69	10.0%
Menin	gococcal Conjugate						
I 90619	49281-0590-05 (5 pack – 1 dose vial)	Meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine .5mL dose, preservative free	MenQuadfi™	\$96.15	\$156.11	\$105.77	10.0%
	49281-0589-05 (5 pack – 1 dose vial)	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135,	Menactra ®	406.45	\$141.70	¢405 75	10.00/
90734	58160-0955-09 (5 pack – 1 dose vial)	quadrivalent (MCV4 or MenACWY), for intramuscular use	Menveo ®	\$96.15	\$148.49	\$105.77	10.0%

2023-24 Vaccine Assessment Grid

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount <u>per</u> <u>dose</u> from 07/01/2022 to 06/30/2023	For Reference: CDC Private Sector Cost/Dose 04/01/2023	<u>dose</u> from 07/01/2023	Percent Change 07/01/2022 to 07/01/2023
Influe	1						
90672	66019-0310-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent	\$18.88	\$23.75	\$20.77	10.0%
90674	70461-0323-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent	\$16.02	\$30.10	\$17.62	10.0%
90686	19515-0814-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent	\$13.50	\$19.73	\$14.85	10.0%
	49281-0423-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR	¥13.30	\$19.76	÷17.05	10.070
90688	49281-0639-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV	\$13.55	\$18.44	\$14.91	10.0%

NOTE: The WVA reserves the right to modify the Assessment Grid in effect at any time with Board approval and appropriate notification of payers.

To ensure proper DBA submission and carrier/TPA remittance to the WVA, providers should check the:

- Date of service to ensure the correct Grid year is being used;

- CPT code to ensure it is a valid code (*see note below); and

- Assessment amount to ensure proper DBA submission and carrier/TPA remittance to the WVA.

*<u>Please note</u>: Sometimes vaccine material is still viable and can be administered, even if it has been discontinued from prior Grids and is not shown on the current Grid. If the CPT code is not offered on the current Grid, providers should check the legacy information at the end of the grid document to determine if a prior Grid amount should be billed on the DBA. Please validate the date of service and the legacy Grid year when selecting the Grid amount.

2023-24 Vaccine Assessment Grid

	DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2023					
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename			
90686	19515-0808-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent			
	49281-0422-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone ® Quadrivalent SYR			
90688	49281-0637-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone ® Quadrivalent MDV			
90672	66019-0309-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist®Quadrivalent			
90674		Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent			

	DISCONTINUED PEDIATRIC INFLUENZA <u>NDC CODES</u> AS OF JUNE 30, 2022						
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename				
90686		Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent				
		Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR				
90688		Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV				
	66019-0308-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist®Quadrivalent				
90674		Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent				

N

2023-24 Vaccine Assessment Grid

	DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2021				
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename		
•		Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent		
		Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone		
90688	49281-0635-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone ® Quadrivalent MDV		
90672	66019-0308-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist®Quadrivalent		
90674		Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent		

	DISCONTINUED PEDIATRIC INFLUENZA <u>NDC CODES</u> AS OF JUNE 30, 2020				
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename		
90686	19515-0906-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent		
90000	49281-0419-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone [®] Quadrivalent SYR		
90672	66019-0306-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist®Quadrivalent		
90688	49281-0631-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone [®] Quadrivalent MDV		
90674	70461-0319-03 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent		

	DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2022 ASSESSMENT GRID				
CPT Code	NDC Code / Packaging	July 1, 2022 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2022	
		NONE		N/A	
	D	ISCONTINUED CPT OR NDC CODES FROM JULY 1, 2020 ASSESSMENT GRIE			
CPT Code	NDC Code / Packaging	July 1, 2021 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2021	
90696	58160-0812-11 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix ®	\$41.93	
90698	49281-0510-05 (5 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel®	\$61.94	
90700	58160-0810-11 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use	Infanrix®	\$18.63	


	DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2019 ASSESSMENT GRID					
CPT Code	NDC Code / Packaging	July 1, 2019 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2019		
90636	58160-0815-52 (10 pack – 1 dose syringe)	Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use. (Age 18 only for CVP)	Twinrix®	\$67.29		

	C	ISCONTINUED CPT OR NDC CODES FROM JULY 1, 2018 ASSESSMENT GRIE)	
CPT Code	NDC Code / Packaging	CPT Code Description July 1, 2018 Grid	Tradename	WVA Assessment Amount per dose as of 7/1/2018
90685	49281-0518-25 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.16
	C	ISCONTINUED CPT OR NDC CODES FROM JULY 1, 2017 ASSESSMENT GRIE		
CPT Code	NDC Code	July 1, 2017 Grid CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2017
90644	58160-0801-11	Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza B vaccine (Hb-MenCY), 4 dose schedule, when administered to high risk children 2 - 15 months of age, for intramuscular use	MenHibrix	\$14.72
90649	00006-4045-41	Human Papilloma Virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil	n/a
90650	58160-0830-52	Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Cervarix	n/a
90743	00006-4981-00	Hepatitis B vaccine, adolescent dosage (2-dose schedule), for intramuscular use (Code price is per dose) (Recombivax HB 10mcg = one dose)	Recombivax HB	\$17.19
90685	49281-0517-25	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.16
90687	49281-0517-25	Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use	Fluzone	\$18.47

Ensuring Funds for Childhood Vaccines

Provider Billing Improvement Plan Discussion Presented to the Washington Vaccine Association Operations Committee Meeting April 25, 2023

Confidential and Proprietary © 2023





Provider Billing Improvement Plan Steps DRAFT for Discussion

